Regulatory Landscape for Biosimilars in Southeast Asia
Regulatory Landscape for Biosimilars in Southeast Asia
The biopharmaceutical landscape is at a pivotal moment as biosimilars—therapeutic products that closely resemble and are clinically equivalent to existing biologic drugs—gain traction. In Southeast Asia, a region characterized by diverse healthcare infrastructures and economic inequalities, biosimilars offer a transformative opportunity to enhance access to essential biologic therapies. Yet, their successful adoption into national healthcare systems depends heavily on regulatory readiness and cross-border alignment.
As regulatory frameworks across the region continue to mature, it is essential for stakeholders—including pharmaceutical companies, regulatory professionals, healthcare providers, and policymakers—to grasp both the shared features and country-specific nuances of biosimilar approval pathways. In this blog, we examine the current biosimilar regulatory landscape in major ASEAN countries, highlight key challenges, and discuss strategies to build a robust and sustainable biosimilar ecosystem.
Know more about our Regulatory Services in Australia
To get the daily updates, follow us on:
Facebook — https://www.facebook.com/DDReg
LinkedIn — https://www.linkedin.com/company/ddregpharma/
Twitter — https://x.com/DDRegPharma
Instagram — https://www.instagram.com/ddreg.pharma/
Comments
Post a Comment